A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)

NCT02326272 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

227

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis
Plaque Psoriasis

Interventions

BIOLOGICAL: Certolizumab Pegol
OTHER: Placebo

Sponsor

UCB Biopharma S.P.R.L.